Search results for "From ACP Journal Club"
Review: In patients with type 2 diabetes who fast, sitagliptin reduces hypoglycemia more than sulfonylurea
Patients who took sitagliptin were significantly less likely to have hypoglycemia during Ramadan, according to a systematic review.
https://diabetes.acponline.org/archives/2015/11/13/6.htm
13 Nov 2015
In high-risk pregnant women, an individualized lifestyle intervention reduced gestational diabetes mellitus
The intervention in the Finnish study targeted women with previous gestational diabetes mellitus or a body mass index of 30 kg/m2 or greater.
https://diabetes.acponline.org/archives/2016/01/08/5.htm
8 Jan 2016
In type 2 diabetes, intensive glucose control for 5.6 years did not differ from usual care for major CV events at 14 years
These long-term follow-up data show no legacy effect from intensive glucose control on cardiovascular (CV) events, differing from the results of the United Kingdom Prospective Diabetes Study, an ACP Journal Club commentary noted.
https://diabetes.acponline.org/archives/2019/10/11/8.htm
11 Oct 2019
In type 2 diabetes, tirzepatide reduced HbA1c vs. semaglutide
This industry-funded trial of tirzepatide, a unimolecular dual agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, heralds a new era of “twincretins” in diabetes management, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/11/12/6.htm
12 Nov 2021
Some antimicrobials increased admissions and ED visits for hypoglycemia in older users of glipizide or glyburide
A study of Texas Medicare patients who took either glipizide or glyburide found that those who were also prescribed certain antibiotics had a much higher rate of hypoglycemic events than those taking an antibiotic not expected to interact with sulfonylureas.
https://diabetes.acponline.org/archives/2015/03/13/7.htm
13 Mar 2015
Review: In type 2 diabetes, sodium–glucose cotransporter 2 inhibitors do not increase major CV events or mortality
The meta-analysis included 37 trials that compared canagliflozin, dapagliflozin, or empagliflozin to placebo or other active antidiabetic treatments.
https://diabetes.acponline.org/archives/2017/02/10/6.htm
10 Feb 2017
SGLT-2 inhibitors were not linked to severe or nonsevere UTIs vs DPP-4 inhibitors or GLP-1 agonists
An ACP Journal Club commentary called the results of this real-world, retrospective study reassuring regarding concerns about associations of urinary tract infections (UTIs) with sodium-glucose cotransporter-2 (SGLT-2) inhibitors.
https://diabetes.acponline.org/archives/2020/01/10/8.htm
10 Jan 2020
Basal insulin plus GLP-1 RA or SGLT2 inhibitor was noninferior to basal-bolus insulin intensification for HbA1c in T2DM
A recent Italian trial showed that regimens with a glucagon-like peptide-1 receptor agonist (GLP-1 RA) or a sodium-glucose cotransporter 2 (SGLT2) inhibitor resulted in less hypoglycemia, but the results may not apply to patients with higher HbA1c levels, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/09/10/7.htm
10 Sep 2021
DPP-4 inhibitors are less effective than metformin for reducing hemoglobin A1c
A meta-analysis of randomized controlled trials comparing dipeptidyl peptidase-4 (DPP-4) inhibitors to metformin and other drugs found that DPP-4 monotherapy is less effective.
https://diabetes.acponline.org/archives/2012/08/10/7.htm
10 Aug 2012
Bariatric surgery improved HbA1c at 5 y more than intensive medical care alone in obese patients with T2DM
A commentary considers the industry-funded STAMPEDE trial, in which obese patients with type 2 diabetes were randomly assigned to intensive medical therapy alone or intensive medical therapy plus Roux-en-Y gastric bypass or sleeve gastrectomy.
https://diabetes.acponline.org/archives/2017/06/09/6.htm
9 Jun 2017